(20) The T69S insertion mutations, associated with resistance to multiple nucleoside analogues, are associated with resistance to tenofovir as well. Tenofovir resistance conferred by the T69S mutation or by multiple thymidine analogue resistance mutations appears to be multiplied if the M184V mutation is replaced by wild-type.(21) The K65R mutation, which may be selected by prior nucleoside analogue therapy, is associated with a modest decrease in sensitivity to tenofovir.
Little is known about the biochemical and virological effects of stopping long-term nucleos(t)ide analogue therapy for hepatitis B e antigen (HBeAg)-negative patients with chronic hepatitis B (CHB).
METHODS:
We performed a cohort observational study, following 33 HBeAg-negative patients with CHB, undetectable serum HBV DNA, and normal levels of aminotransferases after long-term (4 or 5 years) treatment with adefovir dipivoxil (ADV). All patients were followed for 5.
please show us the links or results regarding cure with sequential treatment of tenofovir the peginterferon??? please published in medical/scientific journals..
these studies are still missing the most potent antiviral tenofovir or the combo tenofovir plus entecavir or tenofovir plus telbivudine, although there is probably little difference we do need to know the effect on cccdna of the most potent combos
i hope sooner or later we will have these resports and also the reports of cccdna on intfplus tdf
Hi, BARACLUDE is the tradename for entecavir, a guanosine nucleoside analogue with selective activity against HBV. So you can take entecavir (entegard), which could be the generic form and hence cheaper. Please continue with therapy. Regards.
tenofovir disoproxil fumarate) is a prodrug of tenofovir. The 'disoproxil' is a side chain attached to the active component 'tenofovir'. Inside our body, this side chain gets cleaved off by an enzyme to release the active tenofovir. AGX-1009 has a different side chain attached to the active component 'tenofovir'. It may show higher potency and/or lower toxicity compared to Viread because of this different side chain (At least that's what Agenix is hoping for).
TDF switch effective in Asian chronic HBV patients
Posted in Hepatitis News
Switching therapy to tenofovir disoproxil fumarate is effective in treatment-resistant chronic hepatitis B, show results from a cohort of Asian patients. Administration of TDF resulted in a sustained virological response in the majority of nucleos ide analogue -experienced patients after nearly 2 years of follow-up, report the researchers.
BARCELONA, Spain — The long-term nucleoside and nucleotide analogue treatment of patients with chronic hepatitis B is not associated with an increased risk for extrahepatic cancers, according to results from a new study that led to some confusion.
therefore greater consideration is being given to combined/sequential therapeutic approaches comprising Pegylated-Interferon (PEG-IFN-α) and nucleot(s)ide analogue (NUC) therapy, to achieve this goal. We previously demonstrated boosting of NK cell responses in eAg- patients treated with PEG-IFN-α (Micco et al, J. Hepatol, 2013), and postulated that this effect could be maintained with sequential NUC therapy, representing a superior strategy to NUC monotherapy.
George V. Papatheodoridis1, Christos K. Triantos2, Emilia Hadziyannis1, Konstantinos Zisimopoulos2, Anastasia Georgiou1, Katerina Margariti1, Melanie Deutsch1, Vasiliki Nikolopoulou1, Spilios Manolakopoulos1
INSTITUTIONS (ALL): 1. 2nd Department of Internal Medicine, Hippokration General Hospital of Athens, Athens, Greece.
2. Department of Gastroenterology, University Hospital of Patras, Patras, Greece.
org/posts/Hepatitis-B/A-Potent-HBsAg-Response-to-Treatment-of-HBeAg-positive-Chronic-hepatitis-B-with-Interferon-alpha-plus-a-nucleostide-analogue/show/1637262?personal_page_id=2249050
http://www.medhelp.org/posts/Hepatitis-B/interferon-plus-tenofovir--High-rate-of-HBsAg-loss-predicted-by-baseline-HBsAg-/show/1616127?personal_page_id=2249050
http://www.medhelp.org/posts/Hepatitis-B/Stopping-long-term-NUC-therapy-in-HBeAg-negative/show/1633167?personal_page_id=2249050
http://www.medhelp.
Patient A – HBe-positive, genotype A, F3 fibrosis – had been HBV-DNA negative for 10 months receiving entecavir plus tenofovir. Previous therapy with peg-IFN had been unsuccessful, but now the patient experienced HBeAg seroconversion at week 24. Patient B – HBeAg negative, genotype D, cirrhosis – had a low initial HBsAg level of 16U/l. Receiving entecavir, his HBV-DNA had previously been non-detectable for 27 months. In the remaining 10 patients HBsAg declined only by a mean of 0.
This retrospective study enrolled thirty-eight chronic hepatitis B patients treated with interferon alpha plus a nucleos(t)ide analogue and achieved HBsAg seroconversion during the period from June 2001 to May 2009. Clinical and laboratory data of the patients were collected before and after treatment every 3 months. All patients with HBsAg seroconversion in this study were followed up at least 12 months post-treatment.
This retrospective study enrolled thirty-eight chronic hepatitis B patients treated with interferon alpha plus a nucleos(t)ide analogue and achieved HBsAg seroconversion during the period from June 2001 to May 2009. Clinical and laboratory data of the patients were collected before and after treatment every 3 months. All patients with HBsAg seroconversion in this study were followed up at least 12 months post-treatment.
this remains the best strategy to clear hbv found until now and with highest rates, profund hbvdna suppression for years, tenofovir probably the best or tnf+etv, then add on of interferon
the good thing is also a good decline of hbsag in almost all patients so interferon might be prolonged or stopped and restarted later
One hundred and fifty-two CHB patients treated with peginterferon α-2a plus nucleos(t)ide analogue from Jan 2007 to Sep 2012 were retrospectively investigated. The mean treatment duration was 79 weeks (range 24-120 weeks). Serum HBsAglevels at baseline, week 12, 24, 36, 48, 72, 96 and 120 of treatment were detected
Results: The cumulative HBsAgloss rates of patients treated at 48-week, 96-week and 120-week with peginterferon α-2a plus nucleos(t)ide analogue were 8.55% (13/152), 26.
php
Nucleos(t)ide analogue treatment reduces risk of developing liver cancer and liver cirrhosis among immune tolerant patients
EUROPEAN ASSOCIATION FOR THE STUDY OF THE LIVER
SHARE PRINT E-MAIL
April 15, 2016, Barcelona, Spain: A new study, presented today at The International Liver Congress™ 2016 in Barcelona Spain, demonstrates that the use of antiviral therapy for patients in the immune tolerant phase of Hepatitis B (HBV) prolongs overall survival and reduces the risk of the most co
therapy as soon as possible .. as mentioned above that the long term use of entecavir, tenofovir ...will make fire wall from attack of hcc or cirrohisis ..
i feel this view is very wise ..
for me iam now 38 ..
hbvdna falactuate between 2000-5000 iu/ml
fibisis f1 (last aug)
istarted entecavir to be - in Shallah - in the safe side even though bad effects of entecavir on kidneys ..
Recommended
